Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment

References

• Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Medicine. 2010;363(1):24–7. doi:10.1056/NEJMoa0912217.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Psyrri A, Chaturvedi A. HPV and head and neck cancers: state-of-the-science. Oral Oncol. 2014;50(5):353–355. doi:10.1016/j.oraloncology.2014.03.010.
   PubMed Web of Science ®Google Scholar
• Orlandi E, Iacovelli NA, Tombolini V, Rancati T, Polimeni A, De Cecco L, Valdagni R, De Felice F. Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncol. 2019;99:104453. doi:10.1016/j.oraloncology.2019.104453.
   PubMed Web of Science ®Google Scholar
• Bird T, De Felice F, Michaelidou A, Thavaraj S, Jeannon J-P, Lyons A, Oakley R, Simo R, Lei M, Guerrero Urbano T, et al. Outcomes of intensity‐modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma – a European single institution analysis. Clin Otolaryngol. 2017;42(1):115–122. doi:10.1111/coa.12674.
   PubMed Web of Science ®Google Scholar
• Lawrence MS. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Brit J Cancer. 2014;110(2):489–500. doi:10.1038/bjc.2013.639.
   PubMed Web of Science ®Google Scholar
• Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 2017;19(1):203–217. doi:10.1016/j.celrep.2017.03.037.
   PubMed Web of Science ®Google Scholar
• Brooks JM, Menezes AN, Ibrahim M, Archer L, Lal N, Bagnall CJ, von Zeidler SV, Valentine HR, Spruce RJ, Batis N, et al. Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer. Clin Cancer Res. 2019;25(17):5315–5328. doi:10.1158/1078-0432.CCR-18-3314.
   PubMed Web of Science ®Google Scholar
• Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209–223. doi:10.1038/s41577-021-00574-3.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665–674. doi:10.1038/s41577-019-0221-9.
   PubMed Web of Science ®Google Scholar
• Bhatt KH, Neller MA, Srihari S, Crooks P, Lekieffre L, Aftab BT, Liu H, Smith C, Kenny L, Porceddu S, et al. Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. J Exp Med. 2020;217(10):e20200389. doi:10.1084/jem.20200389.
   PubMed Web of Science ®Google Scholar
• Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–421. doi:10.1038/nature19330.
   PubMed Web of Science ®Google Scholar
• Jadhav RR, Im SJ, Hu B, Hashimoto M, Li P, Lin J-X, Leonard WJ, Greenleaf WJ, Ahmed R, Goronzy JJ, et al. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci USA. 2019;116(28):14113–14118. doi:10.1073/pnas.1903520116.
   PubMed Web of Science ®Google Scholar
• Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, Cui W. CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer. Immunity. 2019;51(6):1028–1042.e4. doi:10.1016/j.immuni.2019.10.009.
   PubMed Web of Science ®Google Scholar
• Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM, Li P, Lin J-X, Konieczny BT, Im SJ, Freeman GJ, et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ Stem-like CD8+ T cells during chronic infection. Immunity. 2019;51(6):1043–1058.e4. doi:10.1016/j.immuni.2019.11.002.
   PubMed Web of Science ®Google Scholar
• Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–1387.e19. doi:10.1016/j.cell.2018.08.039.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. Tcgabiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015;44(8):e71. doi:10.1093/nar/gkv1507.
   PubMed Web of Science ®Google Scholar
• Therneau TM (2022) A package for survival analysis in R. https://cran.r-project.org/web/packages/survival/index.html.
   Google Scholar
• Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, Woo K, Yutani H, Dunnington D Create elegant data visualisations using the grammar of graphics • ggplot2. https://ggplot2.tidyverse.org/.
   Google Scholar
• Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13(1):570–580. doi:10.32614/RJ-2021-053.
   Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e11. doi:10.1016/j.cell.2018.02.052.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Gene Dev. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.118.
   PubMed Web of Science ®Google Scholar
• Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183–199.e9. doi:10.1016/j.immuni.2019.11.014.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110(2):489–500. doi:10.1038/bjc.2013.639.
   PubMed Web of Science ®Google Scholar
• Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, et al. Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer. Nature. 2021;597(7875):279–284. doi:10.1038/s41586-021-03862-z.
   PubMed Web of Science ®Google Scholar
• Chen JH, et al. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response. bioRxiv 2023 04 04 535379. 2023. doi:10.1101/2023.04.04.535379
   Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T cell states associated with response to checkpoint immunotherapy in Melanoma. Cell. 2019;176(1–2):404. doi:10.1016/j.cell.2018.12.034.
   PubMed Web of Science ®Google Scholar
• Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, Mavilio D, Alloisio M, Ferrari F, Lopci E, et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J Exp Med. 2018;215(10):2520–2535. doi:10.1084/jem.20180684.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar